Pay in 4 interest-free payments of $7.23 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats
A medication can reduce appetite, but it does not automatically protect muscle, correct nutrient gaps, or remove the need for follow-up
Pieber , 9 more and Edward John Pratt 5,773 views 3 citations Review 21 May 2025 The evolution of the therapeutic concept GIP receptor antagonism Frederikke Koefoed-Hansen , 4 more and Lrke Smidt Gasbjerg 10,451 views 7 citations Review 17 March 2025 The role of GIPR in food intake control Paula-Peace James-Okoro , 2 more and Frank Reimann 12,710 views 11 citations Review 03 February 2025 The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP Jonathan D
Lancet Diabetes Endocrinol 2020;8:582-93.ArticlePubMed 53
US$ 22.41
US$ 26.34
US$ 29.38
US$ 25.55
US$ 20.01
US$ 20.85
US$ 21.87
US$ 26.00
US$ 24.82
US$ 22.11
US$ 28.53
US$ 25.48
US$ 24.06
US$ 21.80
US$ 25.72
